Bristol-Myers Squibb Co (NYSE:BMY) – Equities research analysts at William Blair lowered their Q1 2019 EPS estimates for Bristol-Myers Squibb in a research note issued to investors on Wednesday. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.95. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2019 earnings at $0.95 EPS, Q3 2019 earnings at $0.97 EPS and Q4 2019 earnings at $0.98 EPS.
Several other equities research analysts also recently commented on BMY. Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a report on Thursday, February 1st. BMO Capital Markets set a $51.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Leerink Swann raised their price objective on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $66.73.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down $0.02 during trading hours on Thursday, hitting $68.96. The company had a trading volume of 10,520,904 shares, compared to its average volume of 9,120,000. The stock has a market cap of $112,870.00, a P/E ratio of 29.22, a P/E/G ratio of 2.14 and a beta of 1.08. The company has a current ratio of 1.55, a quick ratio of 1.46 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb has a 1-year low of $51.56 and a 1-year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $0.63 EPS.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.32%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 67.80%.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now owns 22,000 shares in the company, valued at $1,370,600. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Blue Chip Partners Inc. boosted its position in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the period. Chilton Investment Co. LLC boosted its position in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the period. Keel Point LLC boosted its position in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 39 shares during the period. Finally, Hudock Capital Group LLC boosted its position in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 69.56% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Q1 2019 Earnings Forecast for Bristol-Myers Squibb Co Issued By William Blair (BMY)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/17/q1-2019-earnings-forecast-for-bristol-myers-squibb-co-issued-by-william-blair-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.